Morphinane Synthesis via Safe N-Demethylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for synthesizing morphinane analogues face challenges such as low yields, use of toxic reagents, high costs, and the need for hazardous solvents and high-pressure reactions, which result in inconsistent quality and increased production costs.
Innovation Solution
A novel process using C1-4alkylchloroformate with alkali iodide and a heterogeneous base for N-demethylation, and C1-3alkyl sulfonyl halides for N-alkylation, under moderate conditions, avoiding toxic reagents and improving yields and product purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional N-demethylation methods using cyanogen bromide or ethyl chloroformate are employed, then the morphinane analogues can be synthesized, but the yields are low (65-70%) and toxic reagents are used
Solution Approach 1:
The patent replaces expensive, toxic, and unstable reagents (cyanogen bromide, ethyl chloroformate) with cheap, stable, and safe alternatives (methyl chloroformate, sodium iodide, zinc bromide). These disposable reagents can be handled more safely and provide consistent high yields without the hazards of the traditional reagents.
Solution Approach 2:
The patent changes the chemical parameters of the reaction system by introducing a specific combination of reagents (methyl chloroformate, sodium iodide, zinc bromide) and optimizing reaction conditions (temperature, time, solvent system). This parameter change transforms the reaction efficiency from 65-70% yield to 85-95% yield while eliminating toxicity issues.
2Manufacturing precision
If multiple step processes with intermediate purification are used, then the N-demethylation can be achieved, but the process complexity and production cost increase
Solution Approach 1:
The patent combines multiple reaction steps into a single integrated process. The N-demethylation reaction proceeds directly to completion in one pot using the methyl chloroformate/NaI/ZnBr2 system, eliminating the need for separate intermediate purification steps while maintaining high product purity through the inherent selectivity and efficiency of the reagent system.
3Productivity
If conventional N-alkylation methods are used, then the morphinane analogues can be prepared, but the yields are inconsistent and high costs are incurred
Solution Approach 1:
The patent replaces expensive and unstable N-alkylation reagents (vinyl chloroformate) with cheap and stable alternatives (methyl chloroformate). This substitution provides consistent yields across multiple batches while significantly reducing reagent costs and eliminating the need for costly stability control measures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves higher yields and better product quality with safer reagents and solvents, reducing production costs and environmental impact while ensuring reproducibility.
Implementation Method 1
reacting a compound of formula 2 with methyl chloroformate in presence of an alkali iodide and a base to obtain a compound of formula 3
Implementation Method 2
subjecting the compound of formula 3 to hydrolysis in presence of an acid or a base to obtain a compound of formula 4
Implementation Method 3
reacting the compound of formula 4 with a compound of formula 5 in presence of an C1-3alkyl sulfonyl halide, LiBr and a base to obtain the compound of formula 6
Data Source
AI summary
The present invention relates to an improved process for preparing morphinane analogues of formula 1wherein the substituents R1, R2, R2a, R3, R4, R5 and Y have the meanings as defined in the specifications.